A carregar...

Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome

AIMS: Fibrate medications weakly stimulate the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and are currently employed clinically in patients with dyslipidaemia. The potent and selective agonist of PPAR-α LY518674 is known to substantially increase apolipoprotein A-I (apoA-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Heart J
Main Authors: Khera, Amit V., Millar, John S., Ruotolo, Giacomo, Wang, Ming-Dauh, Rader, Daniel J.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4644252/
https://ncbi.nlm.nih.gov/pubmed/26112886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehv291
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!